219 related articles for article (PubMed ID: 28871815)
1. Pharmacogenetics of aldo-keto reductase 1C (AKR1C) enzymes.
Alshogran OY
Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1063-1073. PubMed ID: 28871815
[TBL] [Abstract][Full Text] [Related]
2. Induction of neoplastic transformation by ectopic expression of human aldo-keto reductase 1C isoforms in NIH3T3 cells.
Chien CW; Ho IC; Lee TC
Carcinogenesis; 2009 Oct; 30(10):1813-20. PubMed ID: 19696165
[TBL] [Abstract][Full Text] [Related]
3. AKR1C enzymes sustain therapy resistance in paediatric T-ALL.
Bortolozzi R; Bresolin S; Rampazzo E; Paganin M; Maule F; Mariotto E; Boso D; Minuzzo S; Agnusdei V; Viola G; Te Kronnie G; Cazzaniga G; Basso G; Persano L
Br J Cancer; 2018 Apr; 118(7):985-994. PubMed ID: 29515258
[TBL] [Abstract][Full Text] [Related]
4. Ruthenium complexes as inhibitors of the aldo-keto reductases AKR1C1-1C3.
Traven K; Sinreih M; Stojan J; Seršen S; Kljun J; Bezenšek J; Stanovnik B; Turel I; Rižner TL
Chem Biol Interact; 2015 Jun; 234():349-59. PubMed ID: 25446855
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence studies of tibolone in premenopausal women and effects on expression of the tibolone-metabolizing enzyme AKR1C (aldo-keto reductase) family caused by estradiol.
Kang KW; Kim YG
J Clin Pharmacol; 2008 Dec; 48(12):1430-7. PubMed ID: 18832293
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics approach to therapeutics.
Koo SH; Lee EJ
Clin Exp Pharmacol Physiol; 2006; 33(5-6):525-32. PubMed ID: 16700889
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.
Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT
Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386
[TBL] [Abstract][Full Text] [Related]
9. Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers.
Veliça P; Davies NJ; Rocha PP; Schrewe H; Ride JP; Bunce CM
Mol Cancer; 2009 Dec; 8():121. PubMed ID: 20003443
[TBL] [Abstract][Full Text] [Related]
10. Aldo-keto reductase 1C subfamily genes in skin are UV-inducible: possible role in keratinocytes survival.
Marín YE; Seiberg M; Lin CB
Exp Dermatol; 2009 Jul; 18(7):611-8. PubMed ID: 19320734
[TBL] [Abstract][Full Text] [Related]
11. Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Shiiba M; Yamagami H; Yamamoto A; Minakawa Y; Okamoto A; Kasamatsu A; Sakamoto Y; Uzawa K; Takiguchi Y; Tanzawa H
Oncol Rep; 2017 Apr; 37(4):2025-2032. PubMed ID: 28259989
[TBL] [Abstract][Full Text] [Related]
12. The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
Perera MA
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):17-28. PubMed ID: 19968573
[TBL] [Abstract][Full Text] [Related]
13. Obstetric therapeutics-how pharmacogenetics may inform drug therapy for pregnant women in the future.
Haas DM
Obstet Gynecol Surv; 2013 Sep; 68(9):650-4. PubMed ID: 25102121
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of genetic variation in carboxylesterase drug metabolism.
Chen F; Zhang B; Parker RB; Laizure SC
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):131-142. PubMed ID: 29264996
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacogenetics and prediction of side effects of drugs].
Harrak M; Khabbal Y; Amarti A; El Hassouni M; Ouldim K
Ann Biol Clin (Paris); 2014; 72(4):405-12. PubMed ID: 25119798
[TBL] [Abstract][Full Text] [Related]
16. [State of the art of pharmacogenetic diagnostics in drug therapy].
Kirchheiner J; Seeringer A; Brockmöller J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Oct; 49(10):995-1003. PubMed ID: 17013776
[TBL] [Abstract][Full Text] [Related]
17. Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily.
Ruiz FX; Porté S; Gallego O; Moro A; Ardèvol A; Del Río-Espínola A; Rovira C; Farrés J; Parés X
Biochem J; 2011 Dec; 440(3):335-44. PubMed ID: 21851338
[TBL] [Abstract][Full Text] [Related]
18. Genetic predisposition to adverse drug reactions in the intensive care unit.
Empey PE
Crit Care Med; 2010 Jun; 38(6 Suppl):S106-16. PubMed ID: 20502164
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics and adverse drug reactions.
Meyer UA
Lancet; 2000 Nov; 356(9242):1667-71. PubMed ID: 11089838
[TBL] [Abstract][Full Text] [Related]
20. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes.
Bauman DR; Rudnick SI; Szewczuk LM; Jin Y; Gopishetty S; Penning TM
Mol Pharmacol; 2005 Jan; 67(1):60-8. PubMed ID: 15475569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
